<div id="readability-page-1"><p>Ayrshire Capital Management LLC lifted its holdings in  Eli Lilly and Company (NYSE:LLY - Free Report) by 13.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor  owned 9,726 shares of the company's stock after acquiring an additional 1,134 shares during the period. Eli Lilly and Company makes up  approximately  3.4% of Ayrshire Capital Management LLC's investment portfolio, making the stock its 9th largest position. Ayrshire Capital Management LLC's holdings in Eli Lilly and Company were worth $7,421,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li></ul><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of  Eli Lilly and Company in the 2nd quarter valued at approximately $27,000.  Evolution Wealth Management Inc. bought a new position in shares of  Eli Lilly and Company during the second quarter valued at $29,000.  Steph &amp; Co. lifted its holdings in  Eli Lilly and Company by 290.0% during the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock worth $30,000 after buying an additional 29 shares during the period.  Financial Gravity Companies Inc. acquired a new position in shares of  Eli Lilly and Company in the second quarter worth approximately $31,000.  Finally, Bare Financial Services Inc lifted its position in shares of  Eli Lilly and Company by 263.6% in the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 29 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of research firms recently issued reports on LLY. Wells Fargo &amp; Company boosted their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, December 10th. Berenberg Bank raised their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a &#34;hold&#34; rating in a report on Tuesday, December 2nd. Guggenheim  reiterated a &#34;buy&#34; rating and set a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Wolfe Research raised their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Tuesday, October 14th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned  a Hold rating to the stock. Based on data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $1,155.36.</p><ul><li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li></ul><p><b>Get Our Latest Research Report on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Stock Down 0.4%</h2><p>LLY opened at $1,075.00 on Thursday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The company's 50-day moving average price is $1,003.00 and its two-hundred day moving average price is $846.93. The stock has a market cap of $1.02 trillion, a price-to-earnings ratio of 52.59, a PEG ratio of 1.09 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. </p><ul><li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 earnings per share. Eli Lilly and Company's revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  As a group, equities analysts expect that  Eli Lilly and Company will post 23.48 earnings per share for the current year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio  is currently 29.35%. </p><h2>Eli Lilly and Company Company Profile</h2> (Free Report)<p>Eli Lilly and Company <span>NYSE: LLY<span></span></span> is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p><h2>See Also</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>The Best $1 You'll Spend This Holiday Season</li><li>Holiday surprise: $1 gets you everything</li><li>America’s “most deplorable” Christmas sale</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li><li>Your family's wealth expires in 2026?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Ayrshire Capital Management LLC increased its stake in Eli Lilly and Company (NYSE: LLY) by 13.2% in Q3, now holding 9,726 shares valued at $7.42 million. The stock represents 3.4% of their portfolio. Other institutional investors have also adjusted their positions in LLY. Analysts have given Eli Lilly a consensus rating of "Moderate Buy" with a target price of $1,155.36. The company reported strong Q3 earnings, beating estimates with $7.02 EPS and $17.60 billion in revenue, a 53.9% year-over-year increase.</p>

Ayrshire Capital Management LLC Has $7.42 Million Stock Position in Eli Lilly and Company $LLY